Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: Modeled Canadian analysis

Osteoporosis International

Volumn 19, Issue 5, 2008, Pages 687-697

  Grima, D T ^a   Papaioannou, A ^b,c   Thompson, M F ^a   Pasquale, M K ^d   Adachi, J D ^b,c  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bisphosphonates; Cost effectiveness; Hip fracture; Model; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; GENERIC DRUG; RISEDRONIC ACID;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CANADA; COST-BENEFIT ANALYSIS; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS; MODELS, BIOLOGICAL; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX;

EID: 43149088493     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0504-z     Document Type: Article

References (42)

1. Rawson NS (2001) "Effectiveness" in the evaluation of new drugs: a misunderstood concept? Can J Clin Pharmacol 8(2):61-62
2. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006
3. ISPOR Real World Task Force. Using 'Real World' Data For Coverage And Payment Decisions: The ISPOR Real World Data Task Force Report. http://www.ispor.org/workpaper/real_world_data.asp Accessed February 2, 2007
4. Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25-34
5. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 Suppl):S1-S34
6. Ontario Drug Benefit Formulary/Comparative Drug Index. No 39. Publications Ontario. Ottawa, Canada
7. Tosteson ANA, Jönsson B, Grima DT et al (2001) Challenges for model-based economic evaluations of post-menopausal osteoporosis interventions. Osteoporos Int 12:849-857
8. Zethraeus N, Borgstrom F, Strom O et al (2007) Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 18:9-23
9. Grima DT, Burge RT, Becker DL et al (2002) Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P and T 27:448-455
10. Kruse H, Kurth A, Moehrke W et al (2005) Impact of bisphosphonates on osteoporotic fractures, patient quality of life and treatment costs: the case of Germany. Value in Health 8(6)
11. Burge R, Saadi R, Ferko N et al (2004) Clinical and economic impact of risedronate treatment for post-menopausal osteoporosis in France. Value in Health 7(6)
12. Saadi R, Burge R, Ferko N et al (2004) Cost-effectiveness of risedronate therapy compared to alendronate in post-menopausal women at high risk of osteoporotic fracture: a Taiwan analysis. Value in Health 7(6)
13. King AB, Burge RT, Worley DJ (2001) Direct medical cost of osteoporosis in the United States: projections for 2000-2025. Value in Health 4(6)
14. Borgstrom F, Carlsson A, Sintonen H et al (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996-1007
15. Eddy D, Johnston C, Cummings S et al (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8(Suppl 4):S1-S88
16. Kanis JA, Oden A, Johnell O et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417-427
17. Tosteson A, Gabriel SE, Grove M et al (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042-1049
18. Sonnenberg F, Beck J (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:332-338
19. Jackson SA, Tenenhouse A, Robertson L (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11:680-687
20. Kanis JA, Oden A, Johnell O et al (2003) The components of excess mortality after hip fracture. Bone 32:468-473
21. Papadimitropoulos EA, Coyte P, Josse RG et al (1997) Current and Projected rates of hip fracture in Canada. Can Med Assoc J 157:1357-1363
22. Jaglal SB, Weller I, Mamdani M et al (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong. J Bone Miner Res 20:898-905
23. Black DM, Palermo L, Grima DT (2006) Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health 9:54-58
24. Kanis JA, Borgstrom F, Johnell O et al (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862-871
25. Kanis JA, Johnell O, Oden A et al (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995
26. Delmas PD, Silverman SL, Watts NB et al (2007) Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: A comparison to patients with minimal bisphosphonate exposure. JBMR 22(Suppl 1):S328
27. Statistics Canada, 1996. Health Reports 8(1)
28. Wiktorowicz ME, Goeree R, Papaioannou A et al (2001) Economic implication of hip fracture: health service use, institutional care and costs in Canada. Osteoporos Int 12:271-278
29. Statistics Canada. Consumer Price Index, health and personal care, by province. http://www40.statcan.ca/l01/cst01/econ161a.htm?sdi= consumer%20price%20index. Accessed January 15, 2007
30. Tomiak M, Berthelot J-M, Guimond E et al (2000) Factor associated with nursing-home entry for elders in Manitoba, Canada. J Gerontol Medical Sciences 55A:M279-M287
31. Tonino RP, Meunier PJ, Emkey R et al (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109-3115
32. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral fracture and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
33. Reginster J, Minne HW, Sorenson OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
34. Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendroante Phase II Osteoporosis Treatment Study Group. N Eng J Med 333:1437-1443
35. Black DM, Cummings SR, Karpf DB et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
36. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
37. Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135
38. Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461-468
39. Roux C, Seeman E, Eastell R et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433-439
40. Black DM, Thompson DE, Bauer DC et al (2000) Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
41. Physician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, D.C. http://www.nof.org/professionals/ clinical.htm Accessed May 7, 2007
42. Epstein S, Cryer B, Ragi S et al (2003) Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 19(8):781-789